hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) Ribupatide, An Oral Dual GLP-1/GIP,
Pay in 4 interest-free payments of $7.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15





.png?ver=V_XikP92lILtNXWLnvc1tA%3D%3D&tx=w_842)














